AU2023221889A1 - Polymorphic forms and methods of producing polymorphic forms of a compound - Google Patents

Polymorphic forms and methods of producing polymorphic forms of a compound Download PDF

Info

Publication number
AU2023221889A1
AU2023221889A1 AU2023221889A AU2023221889A AU2023221889A1 AU 2023221889 A1 AU2023221889 A1 AU 2023221889A1 AU 2023221889 A AU2023221889 A AU 2023221889A AU 2023221889 A AU2023221889 A AU 2023221889A AU 2023221889 A1 AU2023221889 A1 AU 2023221889A1
Authority
AU
Australia
Prior art keywords
crystalline form
compound
degrees
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023221889A
Other languages
English (en)
Inventor
Geoffrey E. Barker
Maureen BARNES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viking Therapeutics Inc
Original Assignee
Viking Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viking Therapeutics Inc filed Critical Viking Therapeutics Inc
Publication of AU2023221889A1 publication Critical patent/AU2023221889A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023221889A 2022-02-18 2023-02-13 Polymorphic forms and methods of producing polymorphic forms of a compound Pending AU2023221889A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263311869P 2022-02-18 2022-02-18
US63/311,869 2022-02-18
PCT/US2023/012898 WO2023158607A1 (en) 2022-02-18 2023-02-13 Polymorphic forms and methods of producing polymorphic forms of a compound

Publications (1)

Publication Number Publication Date
AU2023221889A1 true AU2023221889A1 (en) 2024-08-15

Family

ID=87578977

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023221889A Pending AU2023221889A1 (en) 2022-02-18 2023-02-13 Polymorphic forms and methods of producing polymorphic forms of a compound

Country Status (9)

Country Link
US (1) US20250034183A1 (https=)
EP (1) EP4479409A4 (https=)
JP (1) JP2025508746A (https=)
KR (1) KR20240152889A (https=)
CN (1) CN119053613A (https=)
AU (1) AU2023221889A1 (https=)
CA (1) CA3252569A1 (https=)
MX (1) MX2024010008A (https=)
WO (1) WO2023158607A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
EP1891080A2 (en) * 2005-05-26 2008-02-27 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
WO2020117962A1 (en) * 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Also Published As

Publication number Publication date
JP2025508746A (ja) 2025-04-10
EP4479409A1 (en) 2024-12-25
EP4479409A4 (en) 2025-10-22
US20250034183A1 (en) 2025-01-30
CA3252569A1 (en) 2023-08-24
KR20240152889A (ko) 2024-10-22
MX2024010008A (es) 2024-08-22
WO2023158607A1 (en) 2023-08-24
CN119053613A (zh) 2024-11-29

Similar Documents

Publication Publication Date Title
US11292772B2 (en) Salts of an epidermal growth factor receptor kinase inhibitor
CN104302178B (zh) 表皮生长因子受体激酶抑制剂的固体形式
US20250034183A1 (en) Polymorphic forms and methods of producing polymorphic forms of a compound
US10150770B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
US10301287B2 (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
US11667627B2 (en) Salt and crystal forms of PLK-4 inhibitor
WO2019001383A1 (zh) 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
EP3919498B3 (en) Pyrrolopyrimidine derivative and use thereof
IL280598B2 (en) 6,2- diamino pyridine compounds
CN113423684A (zh) 新型拟甲状腺素药
CN102070618B (zh) 一种化合物及其晶体
JP2025532455A (ja) ナフチルアミン系マイトファジー誘導剤の固体形態、その調製方法、医薬組成物及び使用
US20160074399A1 (en) Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
US20230026869A1 (en) Crystal form of nucleoprotein inhibitor and use thereof
US20240262785A1 (en) Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds
WO2023236877A1 (zh) 苯并[c]色满化合物的可药用盐、其多晶型及用途
US11987582B2 (en) Maleate salts of triazolopyrazine derivatives, compositions, methods of use, and processes of manufacturing the same
WO2019149090A1 (zh) 一种尿酸转运体1抑制剂的晶体及其制备方法和用途
WO2012136121A1 (zh) 氨基苯丙醇类化合物及其用于制备免疫抑制剂的用途
HK40042091A (en) Tmem16a modulators
HK40042091B (en) Tmem16a modulators